Following the investment, Sanofi, Flerie Invest AB and Hadasit Bio will hold approximately 20%, 24% and 48% of KAHR shares, respectively.
KAHR Medical is developing a technology platform known as SCP (Signal Converter Proteins), which allows the construction of protein-based drugs with two functional sides. In contrast to current biological drugs that possess only one functional side, the two functional sides of SCPs allow these drugs to block or activate two reinforcing biological signals at the same time. The SCP platform forms a new generation of biological drugs with great diversity and superior efficacy.
KAHR's leading products, KAHR-101 and KAHR-102, are in pre-clinical development towards treatment of several cancers and autoimmune diseases and are expected to enter clinical trials next year.
About KAHR Medical:
KAHR develops novel drugs that are based on the SCP (Signal Converter Proteins) platform technology for the treatment of cancer and autoimmune diseases. The company's technology is based on many years of research by Dr. Michal Dranitzki Elhalel, Head of Nephrology and a senior researcher at the Hadassah Medical Center, and Professor Mark Tykocinski, Dean of the School of Medicine at Jefferson University in Philadelphia and former Chief of Pathology at the University of Pennsylvania. KAHR Medical is managed by Dr. Noam Shani.
For more information please visit - www.kahr-medical.com
About Hadasit Bio-Holdings:
Hadasit Bio-Holdings, Ltd., established in 2006, is the publicly traded subsidiary of Hadasit Ltd. - the technology transfer comp
|SOURCE Hadasit Bio-Holdings|
Copyright©2012 PR Newswire.
All rights reserved